Get the Stockscreener App
1.17
1.27%
-0.015
Bioaffinity Technologies Inc stock is traded at $1.17, with a volume of 108.90K.
It is down -1.27% in the last 24 hours and down -16.43% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$1.185
Open:
$1.2295
24h Volume:
108.90K
Relative Volume:
0.89
Market Cap:
$17.61M
Revenue:
$321.50K
Net Income/Loss:
$-7.24M
P/E Ratio:
-0.6686
EPS:
-1.7498
Net Cash Flow:
$-5.72M
1W Performance:
-7.87%
1M Performance:
-16.43%
6M Performance:
-56.18%
1Y Performance:
-17.02%
1-Day Range:
$1.03
$1.2295
1-Week Range:
$1.03
$1.33
52-Week Range:
$1.03
$3.62
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
22211 WEST INTERSTATE-10, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
1.17 | 17.61M | 321.50K | -7.24M | -5.72M | -1.7498 |
|
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
|
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
|
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
|
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
|
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
bioAffinity Technologies stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 - Zenopa
bioAffinity Technologies Reports Strong Q3 Growth - TipRanks
bioAffinity Technologies stock hits 52-week low at $1.24 By Investing.com - Investing.com Canada
bioAffinity Technologies Inc (BIAF) Quarterly 10-Q Report - Quartz
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development - Zenopa
bioAffinity appoints new Chief Science Officer By Investing.com - Investing.com Canada
bioAffinity appoints new Chief Science Officer - Investing.com India
bioAffinity Technologies Appoints William Bauta, Ph.D., as Chief Science Officer - citybiz
BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer - TipRanks
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development | BIAF Stock News - StockTitan
J. Michael Edwards Named CFO at bioAffinity Technologies - MPO-mag
SA company sets the stage for Asian expansion - The Business Journals
bioAffinity’s CyPath Lung Test Now Available to U.S. Veterans - MPO-mag
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung - Zenopa
bioAffinity secures Japanese patent for lung health test By Investing.com - Investing.com South Africa
BIAFbioAffinity Technologies, Inc. Latest Stock News & Market Updates - StockTitan
bioAffinity secures Japanese patent for lung health test - Investing.com
bioAffinity Technologies Closes of $2.6 Million Registered Direct Offering & Concurrent Private Placement - citybiz
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
SEC Form 424B5 filed by bioAffinity Technologies Inc. - Quantisnow
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity Technologies Prices of $2.66 Million Registered Direct Offering & Concurrent Private Placement - citybiz
BioAffinity Technologies Down 25% on Stock Sale, Warrant Private Placement - MarketWatch
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement - StockTitan
bioAffinity VP contributes to new cytometry guidelines - Investing.com
bioAffinity VP contributes to new cytometry guidelines By Investing.com - Investing.com South Africa
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines - StockTitan
Lung cancer test speeds growth of San Antonio's bioAffinity - Head Topics
New lung cancer test uses phlegm, machine learning to make early diagnoses - San Antonio Express-News
SA biomed to expand military market under new CFO - The Business Journals
bioAffinity Technologies names J. Michael Edwards as CFO - Investing.com India
bioAffinity Technologies names J. Michael Edwards as CFO By Investing.com - Investing.com Australia
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer - citybiz
bioAffinity Technologies Welcomes Back CFO for Future Growth - TipRanks
bioAffinity Technologies Appoints J. Michael Edwards as Chief Financial Officer - TechBullion
bioAffinity Technologies makes phlegm lung cancer test widely available to Veterans - Mugglehead
Maxim Group Initiates Coverage of bioAffinity Technologies (BIAF) with Buy Recommendation - MSN
BioAffinity Technologies : Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test Form 8 K - Marketscreener.com
bioAffinity Technologies Expands Access to Lung Cancer Test - TipRanks
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test - StockTitan
bioAffinity Technologies secures shareholder nod for warrant exercise - Investing.com
bioAffinity Technologies secures shareholder nod for warrant exercise By Investing.com - Investing.com UK
bioAffinity Technologies (NASDAQ:BIAFW) Shares Up 9.3% - Defense World
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis - BioSpace
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):